EC-Logo-2018_TM_CMYK.jpg
electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
17. Dezember 2024 16:05 ET | electroCore, Inc.
The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
14. November 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Announce Third Quarter September 30, 2024 Financial Results on Wednesday, November 13, 2024
23. Oktober 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
EC-Logo-2018_TM_CMYK.jpg
electroCore Engages FNK IR to Execute Expanded Investor Relations Program
24. September 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has engaged FNK IR, an...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
04. September 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in...
EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Second Quarter 2024 Financial Results
07. August 2024 16:01 ET | electroCore, Inc.
Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023  Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Join Russell Microcap® Index
11. Juni 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the...
EC-Logo-2018_TM_CMYK.jpg
electroCore, Inc. Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
06. Juni 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced...
Logo.png
Cluster Headache Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Lundbeck Seattle Biopharmaceuticals, Clexio Biosciences
29. April 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, April 29, 2024 (GLOBE NEWSWIRE) -- Cluster Headache Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Lundbeck Seattle...
EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
13. März 2024 16:05 ET | electroCore, Inc.
Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY,...